Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Earnings call · FY2025 Q4
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio, 6-K call announcement stay in one workspace.
Management tone
Confident
Net tone +78 · low hedging
Research coverage
3 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Welcome to the Philips 4th Quarter and 4 Year 2025 Results Conference Call on Tuesday, February 10th, 2026. During the call, hosted by Mr Roy Jacobs, CEO and Ms Charlotte Hanneman, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. Please note that this call will be recorded and a replay will be available on the Investor Relations website of Royal Philips. I will now hand the comments over to Ms. Durga Dorosemi, Head of Investor Relations. Please go ahead, Madam. Thank you. Good morning from London, everyone.
Today, we will start by reviewing our fourth quarter and full year 2025 results, followed by a short Q&A session. Then, at 11am, our Capital Markets Day webcast will begin and run until 4pm. You will hear from Roy, Charlotta, and our chief business leaders as they share how we're driving profitable growth to deliver sustainable value. The program continues with a North America-based Philips customer panel, providing real-world customer insights. Roy will wrap up the day with closing remarks and key takeaways. The press release for both events was published on our website this morning. The replay and full transcripts of the webcast, along with the presentations and transcripts for Capital Markets Day will be posted within the next 24 hours. As always, I want to draw your attention to our state public statement on screen. With that, over to you, Ross.
Thanks, Durga, and good morning, everyone. Thank you for joining us today. We have consistently delivered on our commitment in the happy quarter this year, including a strong forward quarter and we are entering 2026 with momentum. This reflects the impact we are making for our customers and consumers, delivered through disciplined execution by our passionate teams. I want to start with three highlights for Q4. Order intake was strong, up 7%, reflecting sustained improvement over the past year as we continue to expand and grow affordable, tracking visibility into 2026 and beyond. Comparable sales growth of 7% year-on-year. It was broad-based across all businesses and geographies, and strong contributions from personal health and connected care businesses continued. Adjusted e-vita margin improved by 160 basis points to 50.1%, despite the impact on tariffs. For the full year, we deliver a strong core intake of 6%, compared with sales growth as for outlook, and adjusted EBITDA margin of 12.3%, exceeding our outlook, and that despite the impact of incremental tariffs. These results reflect margin-accredited innovation, productivity gains, and discipline execution, translating into strong operational performance and cash generation, delivered through performance culture and highly engaged people. As we enter 2026, we are moving from a strengthened foundation and margin improvement focus into the next phase for fillers, one of profitable growth acceleration, with a clear path to missing a rigid still scattered and making its margins by 2028. Now, let's look at our fourth quarter and full year 2025 performance in more detail. Starting with orders. Equipment order intake grew 7%, reflecting sustained momentum over past year. Growth was broad-based across B&T and Connected Care, driven by sustained double-digit growth in North America. We achieved a solid full-year performance with DMP order intake of 5% and connected care of 7%. Orderbook grew 5% year-on-year, with inherent quarterly unevenness. Within DMP, image-guided therapy achieved strong order intake growth, and for staging diagnosis we turned back to growth. Results were driven by a strong demand for a high-end Azurian 7 interventional platform, the epic CBX ultrasound for cardiovascular imaging, and the continued successful ramp-up of our CP5300. In Image Better Therapy, we expanded our relationship with World School Emergency Health, one of the largest US health systems, into a 10-year collaboration spanning 80-plus interventional and reinforcing our role as a role for a partner in Saudi Arabia. You will hear more about this during our North America customer panel discussion and our CMD this afternoon. 32 connected cares. Demand for our monitoring and enterprise informatics solutions was strong. North America remained our strongest road driver. Integrated delivery networks and large health systems continue to invest in enterprise patient intelligence and cybersecurity. Increase me through our enterprise monitoring as a service model in order to improve their clinical, operational and economic outcomes. During the quarter, we signed multiple strategic partnerships with leading U.S. health systems, including Admin Health and UNC-REG. In Enterprise Informatics, we secured a landmark radiology partnership with a large health system in the U.S., standardizing our cloud-based imaging informatics platform hosted on Amazon web services across 27 hospitals. This will support more than four marine imaging studies annually, and enable scalable, efficient, diagnostic workflows. Turning to personal health, we delivered another quarter of sustained, broad-based growth across geographies and businesses. Importantly, this growth was driven by healthy sales trans-cross markets, supported by underlying cat-free growth, resulting in continued market share gain. Demand was particularly strong for one-day shapers and premium portfolios, including high-end shapers and ideal ear removal devices in grooming and duty, as well as the dynamic team series in oral healthcare. In 2025, the accelerated execution of a multi-gear roadmap centered on AI-enabled, patient-centered and scalable innovation platforms across our portfolio thank you for this moment was in december we launched the world's helium free 3d mri verida the world's first ai detector based always on spectral ct system and lumiguide the first real-time ai enabled light-based 3d navigation solution integrated with azurel these innovations are expected to support demand improve mix and contribute to gross margin expansion over time in image guided therapy we close the acquisition of spectra wave in january and i want to welcome the spectra base team to phillips their expertise and leadership in high definition intravascular imaging and angio-based physiological assessment strengthens our innovation leadership in cardiology interventions the largest value pool in interventional procedures for consumers at the china international import expo phillips debuted new oral care grooming and healthcare innovations including the sonicare prestige 9900 and the norelco i9000 prestige reinforcing our commitment to meaningful locally relevant innovation in china As a result, we entered 2026 well-positioned with strong innovation to drive profitable growth over the next three years, supported by a stronger pipeline and innovation platforms designed for scale. We will go into more detail during today's Capital Market Day. This year we continue to make a lot of progress also on our execution priorities, enhancing patient impact and quality, strengthening supply chain resilience, and simplifying our operations. Patient impact and quality remains our highest priority. Embedded across our businesses, innovation, and culture, we deliver tangible improvements in quality performance, including TAPA timelines, significant progress in managing corrections and removals, and we continue year-on-year reductions in non-conformances, complaints, and call rates. We also continue to address the consequences of the RASPORONIC recall and we latency work towards resolution of the FDA warning letter issued last October. We integrally design new innovations and act fast and comprehensively when improving opportunities arise. At the same time, we advance innovation through close regulatory engagement, more than doubling our 510 clearances over the past two years. together this reflects a simpler more standardized quality system that embeds patient impact and quality at design stage enabling high quality innovation to support patients at scale turning to our supply chain we delivered a step change in execution in 2025 building on the stability achieved over the last two years service levels are at all-time highs And lead times are back to competitive levels, despite a significantly more complex global trade environment. Through decisive, disciplined actions, our teams more than offset the impact of incremental tariffs by leveraging productivity improvements, cost discipline, and active mitigation measures in the supply chain. With cross-functional teams fully engaged, we continue to strengthen our footprint in North America. our supplier network but also drive productivity and pricing initiatives as we look ahead to 2026. We are focused on driving disciplined commercial execution with a strong innovation portfolio increasingly oriented toward attractive performance and premium segments, strengthening the order book and accelerating growth over time, turning to the regions. We continue to see healthy, supportive fundamentals across the markets we serve, particularly in North America, where hospital demand remains strong, but the landscape increasingly is segmented, rising costs and workforce shortages on reinforcing consolidation among larger health systems. This, in turn, is driving the demand for secure, productivity-enhancing platforms as hospitals face constraints on people and costs, rising data volumes, and increasing care complexity. This positions Philips' wealth to continue to capture growth reflected in sustained double-digit auto-intake growth in 2025, following double-digit growth in 2024, and we expect North America to remain a key growth engine in 2026 and into the midterm. In China, tender activity gradually increased throughout the last year, obeyed from a low base, supported by stimulus measures. At the same time, the continued expansion of centralized procurement has led to longer processing times and tougher competition, negatively impacting the translation of higher bidder activity into meaningful market growth. As a result, we remain cautious on the near-term output for China while continuing to see attractive long-term growth potential, also in innovation and in sourcing. As a result, we remain cautious going to Europe. In Europe, capital spending remains stable, while select international regions continue to increase investment in healthcare and digitalization as reflected in strong winds in Indonesia and India. In personal health, sellout dynamics in 2025 remained strong across Europe and most growth geographies. Demand in US proved to be resilient. In China, cautious consumer sentiment persisted and demand was subdued, although slightly improved from the prior year. as we move into 2026 we will continue to closely monitor consumer sentiment and market conditions across all regions overall we expect comparable sales growth between the three to four and a half percent range in 2026 led by north america and international regions china's sales growth is expected to be stable. Charlotte will now discuss our fourth quarter performance in more detail and also our outlook for 2026.
Thank you Roy. I will start with segment level performance. In diagnosis and treatment, comparable sales improved sequentially in line with our expected phasing, increasing 4% year-on-year in the fourth quarter and remaining flat for the year within the segment image guided therapy continued to perform particularly well delivering double digit growth in the quarter performance was driven by continued momentum in our flagship Azurian platform and strength in coronary intravascular ultrasound precision diagnosis sales were stable adjusted EBITDA margin in diagnosis and treatment declined by 30 basis points to 11.8% in the fourth quarter this This reflects incremental headwinds from tariffs, which were partially offset by improved cost margin from innovation and productivity measures. For the full year, adjusted EBITDA margin increased by 10 basis points to 11.7%, reflecting solid margin performance despite the impact of tariffs, supported by improved cost margin from innovation and productivity measures. Connected Care closed the year with strong momentum, delivering comparable sales growth of 7% in the fourth quarter and 3% for the full year. Fourth quarter performance was driven by double-digit growth in monitoring and mid-single-digit growth in enterprise informatics, driven by robust order book conversions in North America. Adjusted EBITDA margin in connected care expanded 150 basis points to 16.5% in the fourth quarter, driven by operating leverage, improved cost margin, and productivity measures, partially offset by higher tariffs. For the full year, adjusted EBITDA margin increased by 110 basis points, crossing the double-digit mark to 10.7%. As part of our ongoing portfolio simplification and focus on scalable, higher-margin platforms, we completed the sale of the emergency care business in Q4, in line with the timeline previously communicated. In personal health, comparable sales growth improved sequentially, growing 14% in the fourth quarter and 8% for the full year, with all three businesses contributing. Growth was broad based across geographies. China benefited from an easier comparison base following the impact of inventory destocking last year, which concluded in the second quarter of 2025, with channel inventory at appropriate levels at the end of 2025. Adjusted EBITDA margin in personal health improved 500 basis points to 23% in the fourth quarter, driven by sales growth and productivity measures, partially offset by tariffs and cost inflation. For the full year, adjusted EBITDA margin increased by 130 basis points to 18%. Now, turning to our group results. Comparable sales growth accelerated to 7% in the fourth quarter, with broad-based growth across business segments and geographies, led by strong performance from North America. For the full year, comparable sales growth of 2.3% was in line with our outlook. In the fourth quarter, adjusted EBITDA margin expanded 160 basis points year-on-year to 15.1%, and for the full year, increased 80 basis points to 12.3%. We are particularly pleased with the continued strength of our margin performance this year, driven by sales growth, gross margin improvement from innovation, favorable mix effects, and productivity. This performance more than offset incremental tariff headwinds, which came in slightly better than our expected 150 to 200 million euros range after substantial mitigation. As planned, our proactive and extensive mitigation actions delivered results with measures such as inventory management specialty programs supplier network optimization and selective regionalization efforts reducing the tariff impact we continue to actively work on further mitigating measures including further targeted localization and we are confident in our ability to fully mitigate these headwinds through disciplined execution by 2028 in q4 we delivered 248 million euros in productivity savings bringing total savings to 815 million euros for the year in line with our outlook since 2023 our cost management and productivity initiatives delivered more than 2.5 billion euros exceeding our original outlook of 2 billion euros by the end of 2025. there is more we can and will go after adjusting items for 179 million euros in the quarter compared with 286 million in q4 of last year and 531 million euros for the full year in line with our 300 basis points outlook this compares to approximately 640 basis points last year or 410 basis points excluding litigation provision net of insurance income reflecting our strong commitment to reducing adjusting items over time income tax expense declined by 376 million euros in the quarter mainly driven by the comparative impact of the de-recognition of declared tax assets in the us in q4 2024 and the recognition of deferred tax assets in other jurisdictions in q4 2025 partially offset by higher income before tax in q4 2025. net income increased to 397 million euros in the quarter primarily reflecting improved income from operations and lower tax charges adjusted diluted earnings per share from continuing operations for 60 euro cents in the quarter representing a year-over-year increase of 20 and up 15 for the full year despite significant volatility in major currencies particularly the us dollar the impact on our adjusted ebitda margin and eps was flat reflecting disciplined hedging an optimized currency footprint and targeted commercial actions in markets most exposed to currency fluctuations. We generated 1.2 billion euros of free cash flow this quarter. This was 85 million euros lower year over year, reflecting a tougher comparison base as Q4 2024 included a 367 million euros Resphoronics insurance receipt. For the full year, free cash flow was ahead of our outlook, driven by higher earnings, reaching 512 million euros, after the payment of approximately 1 billion euros in cash related to U.S. medical monitoring and personal injury settlements in the first quarter of 2025. We maintained a disciplined focus on working capital, delivering a strong year-over-year improvement in inventory as a percentage of sales, despite ongoing tariff mitigation initiatives. moving to the balance sheet we ended the quarter with approximately 2.8 billion euros in cash and net depth of approximately 5.3 billion euros our leverage ratio improved to 1.7 times on a net debt to adjusted EBITDA basis from 2.2 times in Q3 and 1.8 times in Q4 2024 driven by higher earnings and stronger cash balances we remain firmly committed to maintaining a strong investment grade credit rating our balance sheet remains strong and we are pleased to offer shareholders the option to receive dividends in shares or cash while continuing to invest in profitable growth now turning to the outlook we enter 2026 from a position of strength with sustained order intake momentum, improved execution, and structural margin, cash, and balance sheet improvements, we are well positioned to accelerate profitable growth in 2026 and beyond. We expect comparable sales growth to accelerate to 3 to 4.5%, driven by order intake momentum, innovation, and improved commercial execution, with all businesses contributing to 2026 growth. Adjusted EBITDA margin is expected to improve to 12.5 to 13%, despite the impact from currently known tariffs and building on the strong margin expansion delivered in 2025. The margin improvement will be driven by growth, continued operational improvement and further productivity, partially offset by the incremental impact of tariffs. In 2026, tariff costs will be fully annualized, resulting in a net impact of 250 to 300 million euros net of substantial mitigations. This assumes that the current tariff levels remain in place throughout 2026. On quarterly phasing, we expect a relatively balanced growth profile in 2026. As a result, all four quarters are expected to be within our full year comparable sales growth range of three to four and a half percent with q1 at the lower end consistent with normal seasonality and following a very strong finish to 2025. Adjusted EBITDA margin is expected to slightly decline in q1 2026 as operational improvements are more than offset by the incremental tariff headlines which will not in effect in the first quarter of the prior year building on the 2.5 billion euro productivity program successfully delivered in the last three years and continuing to focus on what we can control we are launching an additional 1.5 billion euro productivity program for the 2026 to 2028 period adjusting items are expected to be around 200 basis points in 2026 down from 300 basis points in 2025 and we remain committed to further reducing them over time restructuring costs are expected to be roughly 80 basis points and relate to initiatives to drive cost competitiveness, unlock R&D capacity, enhance supply chain agility, and enable central functions to operate at best-in-class cost benchmarks. Other charges, estimated at around 120 basis points, may be related to the Respironics consent degree, field actions, other quality-related and acquisition-related charges. We expect free cash flow in the range of 1.3 to 1.5 billion euros, driven by higher earnings and lower adjusting items. This is expected to be partially offset by a disciplined increase in capital expenditure, supporting growth and regionalization and higher income tax payments associated with improved profitability. This outlook reflects an uncertain macro environment and incorporates currently known tariffs. It excludes any effects of the ongoing Phillips Respironics related proceedings, including the investigation by the US Department of Justice. Now, over to Diorga.
Thank you, Charlotte. Before we move to a brief Q&A session, just a quick request. Please keep questions focused on our Q4 and full year 2025 results and our 2026 outlook. We will be discussing our midterm plans and outlook in more detail at our capital markets day later today. Operator, we are now ready for questions.
Thank you, Madam. if any participant would like to ask a question please press the star followed by two times one on your telephone due to the time please limit yourself to one question and one follow-up this will give more people the opportunity to ask questions there will be a short pause while participants register for a question thank you we will now go to our first question and our first question today comes from the line of Hassan al-Waqil from Barclays. Please go ahead.
Morning, and thank you for taking my questions. I have a couple, please. So firstly, Charlotte, for the last couple of quarters, you've been vocal on the gross margin improvement in the business, and specifically D&T, owing to a better mix in the order book converting. Can you help us understand how this unfolded in q4 and how much of a driver you view the mix benefit as a tailwind to your 2026 margin profile secondly order intake for the full year uh for dnt was five percent um it'd be great if you can help us understand how this differs by modality in q4 and how you can reconcile this with the expect expected slower revenue performance for 2026 and whether this could be an element of conservatism in your guide.
Thank you, Hassan. Let me take your first question on our gross margin improvement. We are indeed, and I indeed have been vocal about that for many quarters, we are very happy with the way our gross margin is developing across Philips. we really see an increase across the board driven also by innovations and productivity as well. And let's keep in mind that gross margin, of course, that's also where our tariffs hit. So, that is impacting that as well. So, we have been very disciplined in executing across the board. So, if I look at 2026, what I think will – what we see from a 2026 perspective also in D&T, we see continued margin expansion despite the tariff impact. So that gives you a good sense of that. We also think that underlying gross margin strength will continue to be strong. So there are a few factors in the bridge for 2026 to think about. First of all, of course, we have the annualizing tariffs. That's a headwind. Then we have continued productivity, and I will talk more about that later. And then the third component, as you say, is also the gross margin of innovation impact. So, all three factors contribute. And then for the second question, maybe over to Roy.
So, if you look to the TNT profile, Hassan, and of course, we were happy with the 5% order intake and the acceleration that we saw towards that 5%. We also see actually order intake momentum continuing. As we said, that's on the back of a very strong North American market that is actually continuing to grow for us double digit in orders. Then we see that if you look to underlying which are the contributors, of course, we have very strong IGP contribution in that mix. We see an acceleration in MR and also Oversound was a good contributor because, you know, we have launched some great new innovations there that have really started to yield very well, including in China. So if you look at the kind of the contribution, you had IDT double digit, then you had the PD business. We saw the acceleration as well, but at a lower pace. Now, that's something that then also when you look into the sales, contributes into your sales conversion. As we know, of course, these are businesses with a bit longer conversion cycles than some of the orders that we have connected here, which were also very strong, but yeah, more who can build in that business. So that's kind of where you see that phasing coming into sales a bit slow. Now that builds into 2026 and we will continue to see stronger momentum and that will also underpin the build of sales into the year. So we'll see, and that's what guided for. And we'll start a bit at the lower end of the range. We see that striking in due course of the year as the order intake momentum that we have also been building up to 2025 really lands well into the rest of the year.
Very helpful. And if I can just follow up on the 26 guide, but also beyond Roy, you know, looking back to 2023, your 25 range was conservative and wide and you've clearly landed at the top end of this and meaningfully outperformed this year's guidance what buffers have you built into the guide for 26 and also beyond that particularly on the margin given the journey from here is going to be a lot harder than the journey from seven and a half percent in 2022 yeah yeah so uh two two parts of answer hassan of course we will go in full detail right at the cnd into kind of our plan underpinning 26 to 28 uh so you will you
You'll have extensive views on that later today. The short answer for today is what we learned in the first plan was that indeed we're living in a dynamic world. So the dynamic world requires that you need to be, on one hand, very diligent in executing your own plan, focus on what you can control, therefore productivity is another important contributor. But as we really started to drive innovation and we have a strong foundation now that we can build on, Growth will be a big contributor as well to margin, bigger than in the first period. So actually that will start to kind of really kick in. And then we keep an eye on an uncertain or dynamic environment where tariffs, for example, in 26 is something that, A, we still will have the full year impact of what's currently known, but you also don't know what could happen next, right? But we have adopted and adapted our organization to a much more agile and leaner one. We're going to be building resilience. We adopt fast or we adapt fast if we see something happening. And that's also on the growth side, right? When we see growth happening in a certain part of the world, we can foster routes to that piece so that we capture that opportunity. And if we see actually a headband popping up somewhere, we can also address that faster.
So I think that is where we kind of will share a bit more later today and this afternoon. but we are kind of taking an outlook that takes the world into account perfect thank you thank you your next question today comes from the line of Richard Felton from Goldman Sachs please go ahead thanks good morning thanks for taking the question and see please the first one within D&T I think precision diagnostics was flat in the quarter I suppose given better order intake across MRI and CT earlier this year I was surprised it was a little bit stronger than that so any colour on precision diagnostics in the quarter and how to think about momentum into 2026 is especially as you're you're bringing new products and new innovation to market and then the second one you referenced that q1 is going to be at the lower end of the the full year 26 growth guidance range I suppose despite the easier comp any sort of other phasing or things to be aware of on that Q1 comments specifically thank you good morning and thanks for your question so first on the your PD question within within DNT so what we've seen play out in Q4 was was in line with expectations orders returned to growth in the imprecision diagnosis and and then from a sales perspective we improved
sequentially and let's not forget of course from a sales perspective we have a higher exposure to China, which is also impacting the sales in the fourth quarter. And if I then take a step back from a PD perspective, as you know, we have really rebuilt the foundation from a quality, from a leadership perspective, we reduced SKUs. You will hear from Jay, our business leader, later today on, well, what we've done and also, very importantly, the plan going forward. So, then, from a PD perspective, from a margin perspective, you will have seen progression. We went from mid-single digits to high-single digits, and later today, we'll explain that there's much more to come. And also, the innovation that we spoke about and that Hassan asked about earlier is accretive and now turning into a tailwind, particularly related to the RSA innovations that Roy mentioned on the call earlier. That, in combination with stronger commercial and service execution, makes us feel very good about 2026, and will also drive a stronger funnel and order intake in 2026. So, that is on your first question. Your second question was on the Q1 phasing that you asked if there were any impacts there. So, as I said in my prepared remarks, our growth phase is much, much more balanced than in 2025. We have a very balanced progression in 2025, and actually all quarters are in the 3% to 4.5% range, which is a significant improvement from where we were last year, so we're pleased about that. Now, Q1 indeed, as you said, starts at the lower end, a couple of reasons, nothing out of the ordinary there. on the one hand, it's just seasonality. Q1 is typically our lowest quarter, as you know, and then, of course, we had a strong finish in Q4 as well. So that's from a sales perspective. From a margin perspective, as I also said in the prepared remarks, look, the tariffs continues to be a significant headwind, and that is particularly impacting us in Q1, because the operating leverage from stronger sales really only kicks in at the end of the year, primarily so q1 from that perspective is a little bit lighter and that's where our tariff kicks in strongly but as i said on the preparatory marks as well we are very committed to margin expansion our guide also includes a margin expansion of 20 to 70 basis points so we go very hard at driving that thank you very much and look forward to hearing more this afternoon thank you your next
Next question today comes from the line of Julien Donois from Jefferies. Please go ahead.
Good morning, Roy. Good morning, Charlotte, and congratulations on a strong quarter and a very nice 1928. I have two questions, if I may, as well. The first one relates to personal health, which obviously was super strong in Q4 and accelerating sequentially, and this is despite tough comps in the quarter, so just curious whether there is any kind of stocking effect into that or is it just the very strong demand you highlighted for Europe and elsewhere and the second question is more broad, it's just whether you have an update and a stance on the section 232 investigation that's been running by the US government any thoughts you might want to share on that side please, it would be helpful, thank you Thank you very much, Julien and let me take your first question on
personal health, we were indeed very very pleased with our strong personal health performance in the quarter, 14% in Q4, actually not on a very tough comp though. So what has been driving this strong growth, a few different things. First of all, we saw market share gains really across all businesses. Second of all, and this is very easy to see, very healthy sellout trends across most geographies And also a very resilient plant in North America. And that is where the combination of our innovations, that Roy also mentioned, combined with our strong commercial execution, really, really solid. And particularly on your stocking question, I also said it in the prepared remark, we have, as we promised we would do, de-risked the China trade inventory.
And it is now roughly at three months, whereas a year ago, it's now in line. on that so nothing further to add there let me take the second question on the 232 so actually 232 investigation has not been concluded nor any outcome shared how we look at it is that in essence it's equal to terrorists but a different way of going after it right so i think this is a potential measure that could think this will worst situation but we don't speculate if you bring some tariffs on we are of course
you know they're looking into measures that potentially could benefit but thank you very much thank you your next question today comes from the line of veronica double jova from city please go ahead excellent um good morning and thank you for taking my questions i'll keep it to two um and also short term.
First, I just want to get your flavor for China. Obviously, we've had you guys to flat China in 26. Healthineers have done the same. GE Healthcare, arguably whose mix is closer to yours, have expressed some more cautiousness. They expect China revenues to decline in 26. So just if you can talk a little bit to the building blocks of that assumption and what you're seeing in that market at the moment, that would be my first one. And then Charles, if I can come back on that pH margin in the fourth quarter. I followed your stock for a very long time. I went back through the history, and I think the best margin you ever achieved in pH in the fourth quarter was 21%. So the 23%, especially with tariffs, is highly unusual. Can you maybe talk to some of the structural changes that have happened in the business that are enabling you to drive this, you know, substantially better margin dynamic that we have seen in pH versus what we have seen in pH in the past? Thank you guys so much.
Thank you, Veronica. Let me take the first one on China. So in China, so we see the following as I also highlighted in my remarks. So actually we see China stabilizing in 2026. So of course it was a headwind in the last plan period and also in 2025 with stabilizing. So actually we expect contribution from China, but we are remaining cautious on it. So we see two different trends, one in pH, where actually we have seen step-by-step some improvement in the sellout, and we expect that will also kind of result in improvement in selling and therefore sales in the China market. Now, on the health system side, we remain more cautious because the outlook on tenders and how they convert into real orders is still less predictable. And therefore, kind of, we are counting for growth, especially on the health system side, much more on a very strong North America and also the other parts of the world. So that is kind of where we remain cautious overall. We still remain committed to it. We see a slightly differentiated picture between pH and D&T, but we do see the kind of China contributing to growth, although to a lesser extent than any other region.
Yeah, thanks, Veronica. Monica, let me take your second question on the pH margin in Q4. Of course, we're very pleased with that strong margin, and in Q4 particularly also driven by the operating leverage on the back of 14% sales. But if you think about the more structural drivers, I would call out a few, and also Deepta will explain more later today, so that is something to look forward to as well. But the key drivers, first of all, innovation. I mean, Roy spoke about the innovations we have, for instance, the new platform for Sonicare. We have OneBlade that is doing extremely well. Those innovations, they come at a higher margin, and they also drive premiumization, which also helps to drive higher margin and also drive higher prices. The second component is really around commercial execution, which has been very, very strong in personal health. We, of course, win with the winners, the Amazons of the world and the JDs of the world. And that continues to be a very strong force for us as well. And then thirdly, and this goes for all of Philips, we really focus on productivity, on disciplined execution, on controlling the controllables. And all those three factors really, really helped us also in Q4 2025. And as I said, Dieter will explain later how we are confident that we will also further improve over the next three years.
That's very helpful, Charlotte, and I can maybe just quickly follow up. I think, you know, originally at the third quarter, you talked about sort of high single digit growth in pH. It's obviously coming almost at twice the pace that I think many of us expected.
Anything you'd call out, is there a specific region or a specific category that helps drive this meaningful supply than the revenues yeah thank you uh thank you veronica i would say it's pretty broad-based broad-based overall and both from a business and a geographical perspective we just saw very good momentum across the board as there's really a lot of demand for our product so we saw a really good performance in grooming where and i spoke about the one blade platform just now, we see very, very good traction across the board. And just as a reminder, in Q4, we, of course, benefited from the lower comparable due to China, because last year we were still in full de-stocking mode, so that has helped absolutely as well. So, but also, excluding China, the numbers were still very, very strong. Thanks, Veronica. Thank you, guys.
Thank you. We will now take our final question for today. And the final question comes from the line of Hugo Solvay from BNP Paribas. Please go ahead.
Thanks for taking my questions and congrats on the pre-ins. Two, please. First, on the drivers for the NTNCC Connected Care Demand, patient volumes in the U.S. was not mentioned in the Q3 slide deck, so just wondering what magnitude of pickup you're seeing and how sustainable do you think it is. And on the Q1 margin comments, you expect to decline slightly. Is the decline that we've seen in Q1 2025 would be a good proxy for Q1 2026? Just trying to think about where we should land.
Yeah, thank you. Let me take the first one in terms of strong demand in terms of the U.S. We've seen a few drivers, especially big investment in infrastructure in healthcare systems in the U.S. is driving significant uptake and demand for platforms. So if you look, some of the CapEx spend, and even if you look kind of the demand forecast on CapEx, really highlights that they're strengthening monitoring. They're strengthening cybersecurity as a big priority, which, of course, also plays to our informatics business, both in imaging and, again, in monitoring. And, therefore, we have seen significant kind of momentum in North America on the connected care side. We expect that also to continue into 2025. Now, that, of course, is also driven by strengthening of the financial health of the healthcare systems in the U.S., Not all, as we know, so the stronger systems are getting stronger. They are consolidating and actually absorbing some of the smaller systems. But again, that then plays to our platform play because that actually is why they like us, because we can provide the core infrastructure for interventional, for cardiac, for monitoring. So those are really key drivers for us that actually have been helping us in 2025. and actually see prolonged, strong demand on that in 26 and beyond. And actually, I think what will be very helpful today is the customer panel as well, because they will talk exactly about their needs to drive more reliability in their operations. So they're pretty investing behind that, because with the staff shortages, they need to make sure that they have actually systems that support the staff in the best possible way so that they can deal with patients, because patient volume is actually strong and good. Also, procedures are expanding at what we did also with SpectraWave, bolstering of our cardiology play is because we see that procedure momentum in cardiology and the patient volume in cardiology, especially continuing to grow. That's actually where we are very well positioned to capture that across our portfolio with also the imaging part, the monitoring part, and the interventional suite. Thank you, Roy. let me take your your second question on the on the q1 margin uh hugo i would say um it's not a bad proxy uh to say uh to take the decline that we we saw in q1 2020 and 25 so um that's roughly right thank you super helpful thank you thank you all that was the last question mr jacobs please continue yeah thank you all let me close we delivered our outlook in 2025 consistently across all four quarters order intake was healthy sales growth improved sequentially margins expanded and cash generation was strong despite ongoing tariffs these results demonstrate our strength and foundation improved resilience and disciplined execution in a challenging micro environment this is how we deliver our innovations to consumers and customers across the globe where we see demand for them strengthening. Above all, I also really want to thank all our employees globally for very hard work, delivering these strong results whilst making a meaningful difference through our impacted care culture and delivering better care for more people. With sustained auto momentum, a robust innovation pipeline, clear focus on accelerating profitable growth, and a continued dedication of our teams worldwide, Philips is well positioned to meet our outlook for 2026 and beyond. We look forward to sharing many more details at today's Capital Markets Day starting at 11am. I really invite you to be there. Thank you so much, looking forward.
Thank you. This concludes the Royal Philips Fourth Quarter and Full Year 2025 Resorts Conference Call on Tuesday, February 10th, 2026. Thank you for participating.
26:22 to 50:43 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Morning, and thank you for taking my questions. I have a couple, please. So firstly, Charlotte, for the last couple of quarters, you've been vocal on the gross margin improvement in the business, and specifically D&T, owing to a better mix in the order book converting. Can you help us understand how this unfolded in q4…
Charlotte Hanneman: Thank you, Hassan. Let me take your first question on our gross margin improvement. We are indeed, and I indeed have been vocal about that for many quarters, we are very happy with the way our gross margin is developing across Philips. we really see an…
Also speaking: Roy Jakobs, Speaker 2
Good morning, Roy. Good morning, Charlotte, and congratulations on a strong quarter and a very nice 1928. I have two questions, if I may, as well. The first one relates to personal health, which obviously was super strong in Q4 and accelerating sequentially, and this is despite tough comps in the quarter, so just…
Charlotte Hanneman: personal health, we were indeed very very pleased with our strong personal health performance in the quarter, 14% in Q4, actually not on a very tough comp though. So what has been driving this strong growth, a few different things. First of all, we saw market…
Also speaking: Roy Jakobs
First, I just want to get your flavor for China. Obviously, we've had you guys to flat China in 26. Healthineers have done the same. GE Healthcare, arguably whose mix is closer to yours, have expressed some more cautiousness. They expect China revenues to decline in 26. So just if you can talk a little bit to the…
Roy Jakobs: Thank you, Veronica. Let me take the first one on China. So in China, so we see the following as I also highlighted in my remarks. So actually we see China stabilizing in 2026. So of course it was a headwind in the last plan period and also in 2025 with…
Also speaking: Charlotte Hanneman
Thanks for taking my questions and congrats on the pre-ins. Two, please. First, on the drivers for the NTNCC Connected Care Demand, patient volumes in the U.S. was not mentioned in the Q3 slide deck, so just wondering what magnitude of pickup you're seeing and how sustainable do you think it is. And on the Q1 margin…
Roy Jakobs: Yeah, thank you. Let me take the first one in terms of strong demand in terms of the U.S. We've seen a few drivers, especially big investment in infrastructure in healthcare systems in the U.S. is driving significant uptake and demand for platforms. So if you…
SEC call announcement
Filed Feb 10, 2026 · complete as-filed document